Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst Pharmaceuticals (BCRX) announced significant findings from the APeX-2 trial for ORLADEYO (berotralstat), demonstrating an 80% average reduction in monthly hereditary angioedema (HAE) attacks. The treatment was well-tolerated, with 81% of patients completing the trial. Additional presentations at the EAACI Congress revealed a 78-85% reduction in the use of on-demand medications for patients with significant attack rate reductions. Long-term data underscores the drug's efficacy and safety, crucial for patient demand as therapy shifts from injectables to oral solutions.
BioCryst Pharmaceuticals (BCRX) announced multiple data presentations at the EAACI Hybrid Congress from July 10-12, 2021. Key presentations include:
- Phase 3 APeX-2 Study: Durable reduction in hereditary angioedema (HAE) attack rates with berotralstat.
- APeX-S Subgroup Analysis: Low attack rates in adolescent patients.
- Reduction in On-Demand Medications: Berotralstat's efficacy in HAE treatment.
ORLADEYO (berotralstat) is approved for prophylaxis of HAE attacks in patients 12 years and older.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has secured a crucial partnership with Neopharm Ltd. for the exclusive commercialization of ORLADEYO in Israel. The Israeli Ministry of Health has accepted the regulatory submission for ORLADEYO, which is aimed at preventing recurrent attacks in patients with hereditary angioedema aged 12 and older, and has granted an accelerated review. This collaboration will leverage Neopharm's expertise in rare diseases to enhance market access and support commercialization efforts in Israel and the Palestinian Authority.
BioCryst Pharmaceuticals (BCRX) announced the availability of ORLADEYO™ (berotralstat) in Germany for patients with hereditary angioedema (HAE). The European Medicines Agency approved the drug on April 30, 2021, for preventing recurrent HAE attacks in individuals aged 12 and above. BioCryst aims to meet the significant demand for targeted oral therapies in Europe, with plans for further launches across the continent. ORLADEYO is the first oral therapy specifically designed for HAE prevention and is available in multiple regions, including the U.S. and Japan.
BioCryst Pharmaceuticals (Nasdaq:BCRX) will present at two virtual healthcare conferences: the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET, and the JMP Securities Life Sciences Conference on June 17, 2021, at 1:30 p.m. ET. Investors can access live audio webcasts and replays via the Investors section on BioCryst's website. The company focuses on developing oral medications for rare diseases, including ORLADEYO™ for HAE attack prevention and other investigational therapies.
BioCryst Pharmaceuticals (BCRX) announced that the UK’s MHRA has granted marketing authorization for ORLADEYO™ (berotralstat) as the first oral therapy for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older. This approval marks a significant step in providing patients with a convenient treatment option, potentially improving their quality of life. Clinical trial data showed ORLADEYO reduced HAE attack rates significantly, from 2.9 to 1.0 attacks per month over 48 weeks. The NICE and SMC decisions for NHS use are expected in Q4 2021.
BioCryst Pharmaceuticals reported Q1 2021 net revenue of $10.9 million from ORLADEYO, marking a strong launch for its oral treatment for hereditary angioedema (HAE) in the U.S. The drug is now approved in the U.S., Japan, and the EU. Total revenues reached $19.1 million, up from $4.8 million a year earlier. R&D expenses increased to $42.4 million, reflecting investments in the BCX9930 program. The net loss widened to $64.3 million, or $0.36 per share. With $244.4 million in cash, the company expects its resources to last into 2023.
BioCryst Pharmaceuticals (Nasdaq:BCRX) announced its participation in two upcoming virtual healthcare conferences. The company will present at the Bank of America 2021 Healthcare Conference on May 12, 2021, at 12:30 p.m. ET, and at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:20 p.m. ET. Interested parties can access links to live audio webcasts and replays in the Investors section of BioCryst’s website.
BioCryst focuses on discovering novel, oral medicines for rare diseases.
BioCryst Pharmaceuticals (BCRX) announced that the European Commission has approved ORLADEYO™ (berotralstat) for preventing recurrent hereditary angioedema (HAE) attacks in patients aged 12 and older. This approval marks ORLADEYO as the first targeted oral prophylactic therapy in Europe, catering to a significant unmet need. The company plans to launch ORLADEYO in Germany this quarter, with other European markets to follow. In trials, ORLADEYO significantly reduced attack rates and was well tolerated, prompting optimism about its market acceptance and potential impact on patient care.
BioCryst Pharmaceuticals, Inc. (BCRX) will report its first quarter 2021 financial results on May 6, 2021. A conference call and webcast will occur at 8:30 a.m. ET to discuss the results and provide corporate updates. Interested parties can access the call via phone or through a live webcast on BioCryst's investor website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases, with products like ORLADEYO™ approved for HAE attacks and several ongoing development programs.